Laboratory testing for fibrinogen abnormalities

American Journal of Hematology

Volumn 83, Issue 12, 2008, Pages 928-931

  Verhovsek, Madeleine ^a   Moffat, Karen A ^a,b   Hayward, Catherine P M ^a,b,c  

^a MCMASTER UNIVERSITY   (Canada)

^b HAMILTON REGIONAL LABORATORY MEDICINE PROGRAM   (Canada)

^c MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOGEN;

AFIBRINOGENEMIA; BLEEDING; BLOOD CLOTTING TEST; DYSFIBRINOGENEMIA; FIBRIN CLOT; HUMAN; HYPOFIBRINOGENEMIA; INTERNATIONAL NORMALIZED RATIO; LABORATORY TEST; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; REVIEW; THROMBIN TIME;

AFIBRINOGENEMIA; BLOOD COAGULATION TESTS; FIBRINOGENS, ABNORMAL; HUMANS;

EID: 56749125053     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21293     Document Type: Review

References (27)

1. Colman RW, Marder VJ, Clowes AW, et al. Hemostasis and Thrombosis: Basic Principles and Clinical Practice, 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2006.
2. Mosesson MW. Fibrinogen and fibrin structure and functions. J Thromb Haemost 2005;3:1894-1904.
3. Cerneca F, Ricci G, Simeone R, et al. Coagulation and fibrinolysis changes in normal pregnancy. Increased levels of procoagulants and reduced levels of inhibitors during pregnancy induce a hypercoagulable state, combined with a reactive fibrinolysis. Eur J Obstet Gynecol Reprod Biol 1997;73:31-36.
4. Gjonnaess H, Fagerhol MK, Stormorken H. Studies on coagulation and fibrinolysis in blood from puerperal women with and without oestrogen treatment. Br J Obstet Gynaecol 1975;82:151-157.
5. Deutsche E. Blood coagulation changes in liver disease. Prog Liver Dis 1965;2:69-83.
6. Famodu AA, Adedeji MO, Reid HL. Serial plasma fibrinogen changes accompanying sickle cell pain crisis. Clin Lab Haematol 1990;12:43-47.
7. Irish A. Cardiovascular disease, fibrinogen and the acute phase response: Associations with lipids and blood pressure in patients with chronic renal disease. Atherosclerosis 1998;137:133-139.
8. Rice EW. Plasma fibrinogen, cholinesterase activity, and anemia: Utility of fibrinogen in multiphasic screening and in assessing the activity of diseases. Clin Chem 1977;23:741-742.
9. Haire WD. Pharmacology of fibrinolysis. Chest 1992;101:91S-97S.
10. Lechner K, Niessner H, Thaler E. Coagulation abnormalities in liver disease. Semin Thromb Hemost 1977;4:40-56.
11. Mannucci PM, Duga S, Peyvandi F. Recessively inherited coagulation disorders. Blood 2004;104:1243-1252.
12. Peyvandi F, Kaufman RJ, Seligsohn U, et al. Rare bleeding disorders. Haemophilia 2006;12 (Suppl 3):137-142.
13. Acharya SS, Coughlin A, Dimichele DM. Rare Bleeding Disorder Registry: Deficiencies of factors II, V, VII, X, XIII, fibrinogen and dysfibrinogenemias. J Thromb Haemost 2004;2:248-256.
14. Francis JL, Armstrong DJ. Sialic acid and enzymatic desialation of cord blood fibrinogen. Haemostasis 1982;11:223-228.
15. Martinez J, Keane PM, Gilman PB, Palascak JE. The abnormal carbohydrate composition of the dysfibrinogenemia associated with liver disease. Ann NY Acad Sci 1983;408:388-396.
16. Van Cott EM, Smith EY, Galanakis DK. Elevated fibrinogen in an acute phase reaction prolongs the reptilase time but typically not the thrombin time. Am J Clin Pathol 2002;118:263-268.
17. Quick AJ, Hussey CV, Geppert M. Prothrombin: Analytical and clinical aspects. Comparison of the one- and two-stage methods. Am J Med Sci 1963;246:517-526.
18. Latallo ZS, Teisseyre E. Evaluation of Reptilase R and thrombin clotting time in the presence of fibrinogen degradation products and heparin. Scand J Haematol Suppl 1971;13:261-266.
19. Langdell RD, Wagner RH, Brinkhous KM. Effect of antihemophilic factor on one-stage clotting tests; a presumptive test for hemophilia and a simple onestage antihemophilic factor assy procedure. J Lab Clin Med 1953;41:637-647.
20. Clauss A. Rapid physiological coagulation method in determination of fibrinogen. Acta Haematol 1957;17:237-246.
21. Chitolie A, Mackie IJ, Grant D, et al. Inaccuracy of the 'derived' fibrinogen measurement. Blood Coagul Fibrinolysis 1994;5:955-957.
22. Laurell CB. Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies. Anal Biochem 1966;15:45-52.
23. Haverkate F, Samama M. Familial dysfibrinogenemia and thrombophilia. Report on a study of the SSC Subcommittee on Fibrinogen. Thromb Haemost 1995;73:151-161.
24. Lak M, Keihani M, Elahi F, et al. Bleeding and thrombosis in 55 patients with inherited afibrinogenaemia. Br J Haematol 1999;107:204-206.
25. Mosesson MW. Dysfibrinogenemia and thrombosis. Semin Thromb Hemost 1999;25:3111-319.
26. Marchi R, Mirshahi SS, Soria C, et al. Thrombotic dysfibrinogenemia: Fibrinogen "Caracas V" relation between very tight fibrin network and defective clot degradability. Thromb Res 2000;99:187-193.
27. Siebenlist KR, Mosesson MW, Meh DA, et al. Coexisting dysfibrinogenemia (gammaR275C) and factor V Leiden deficiency associated with thromboembolic disease (fibrinogen Cedar Rapids). Blood Coagul Fibrinolysis 2000; 11:293-304.